GlycA, a novel inflammatory marker, is associated with subclinical coronary disease

Abstract

CVD ancillary study, was involved in the CT data collection, and provided critical revisions to the paper. Dr. Budoff interpreted the cardiac CT scans for the study (CT Core Lab) and provided critical revisions to the paper. Dr. Otvos provided the GlycA measurements and provided critical revisions to the paper. Drs. Zhao, Brown, Guallar, Palella, Martinson, Akinkuolie, Haberlen, and Mora provided critical revisions to the paper. Dr. Michos, Fashanu, and Tibuakuu take full responsibility for its content. All authors reviewed the final draft and approve of its submission. The manuscript was also approved by the MACS Executive Committee. Disclosures: Dr. Brown has served as a consultant to Gilead Sciences, Merck, BMS, EMD-Serono, and Theratechnologies. Dr. Budoff has received research funds from GE Healthcare. Dr. Otvos is employed by LabCorp (formally LipoScence). Dr. Mora has received research grant support from Atherotech Diagnostics, and has received consulting fees from Quest Diagnostics for work outside the current study. Dr. Mora has a patent application on the use of GlycA for predicting risk of colorectal cancer. No other authors report any conflicts.

The novel inflammatory marker GlycA and the prevalence and progression of valvular and thoracic aortic calcification: The Multi-Ethnic Study of Atherosclerosis

“…However, both the prevalence and incidence of DTAC (at 27% and 11%) was greater than the other 3 ECC markers, so there may be less statistical power to detect associations for the other ECC markers. Of note, DTAC has been shown to be associated with CAC 42 , and CAC has a positive association with GlycA 8 . Alternatively, there may be distinct biological mechanisms that lead to preferential calcification across the various vascular beds.…”

“…Prior studies have examined the relationship between GlycA and subclinical coronary artery disease (CAD) as measured by CAC score on non-contrast CT or coronary plaque by coronary CT angiography. 8,31 In a case-control study involving patients with psoriasis, GlycA was found to be associated with subclinical CAD beyond ASCVD risk factors and hsCRP. 31 In another cross-sectional study conducted in patients with rheumatoid arthritis, GlycA was correlated with the presence of CAC and prevalent CAD.…”

GlycA, a Novel Inflammatory Marker and Its Association With Peripheral Arterial Disease and Carotid Plaque: The Multi-Ethnic Study of Atherosclerosis

“…4,[35][36][37][38][39] In several cross-sectional studies, there were strong positive associations between GlycA and coronary atherosclerosis among individuals with rheumatoid arthritis, 35 psoriasis, 40 and HIV infection. 20 In a study of participants undergoing cardiac catheterization, GlycA was strongly associated with the presence and extent of coronary artery disease and positively associated with cardiovascular and noncardiovascular mortality. 36 Similarly, a prospective cohort study found an association between baseline GlycA and incident CVD risk occurring over a median follow-up time of 17.2 years.…”

“…37 Several other studies have shown similar positive associations between GlycA and incident CVD, mortality, and cancer 4 and have shown that the relationship with CVD was stronger for GlycA than that reported for hsCRP 38 and is independent of hsCRP. 39 Despite the aforementioned established association of GlycA with incident CVD events 4 and with subclinical coronary and extra-coronary atherosclerosis, 20,21,40 the relationship of GlycA with subclinical and clinical PAD, specifically, had not been previously established. Although there are some common shared cardiovascular risk factors that promote atherosclerosis across various vascular beds, risk factors are not necessarily overlapping.…”

“…18 In prior work from the Multi-Ethnic Study of Atherosclerosis (MESA), plasma GlycA levels were associated with poorer cardiovascular health at baseline 19 and with increased risk of incident CVD events and all-cause mortality, even after adjustment for other inflammatory markers such as hsCRP, D-dimer, and IL-6. 4 GlycA has also been shown to be associated with several measures of subclinical atherosclerosis, including prevalent coronary artery calcium 20 as well as prevalent calcification in the thoracic aorta and aortic valve. 21 However, the associations of GlycA with atherosclerotic disease specifically located in the peripheral arteries and carotid arteries have not yet been established.…”